GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Cash And Cash Equivalents

Regeneron Pharmaceuticals (WBO:REGN) Cash And Cash Equivalents : €1,784 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Cash And Cash Equivalents?

Regeneron Pharmaceuticals's quarterly cash and cash equivalents declined from Dec. 2023 (€2,503.41 Mil) to Mar. 2024 (€2,393.84 Mil) but then stayed the same from Mar. 2024 (€2,393.84 Mil) to Jun. 2024 (€1,784.33 Mil).

Regeneron Pharmaceuticals's annual cash and cash equivalents increased from Dec. 2021 (€2,553.76 Mil) to Dec. 2022 (€2,931.97 Mil) but then declined from Dec. 2022 (€2,931.97 Mil) to Dec. 2023 (€2,503.41 Mil).


Regeneron Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cash And Cash Equivalents Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,456.02 1,803.22 2,553.76 2,931.97 2,503.41

Regeneron Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,788.04 2,016.71 2,503.41 2,393.84 1,784.33

Regeneron Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Regeneron Pharmaceuticals  (WBO:REGN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Regeneron Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).